REZILIENT3 Zipalertinib Data and the Negative FURVENT Readout

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, notes that in the phase 3 REZILIENT3 trial, presented at the 2026 World Conference on Lung Cancer, adding zipalertinib to chemotherapy extended progression-free survival (PFS) by 6 months in first-line EGFR exon 20 insertion–mutated non–small cell lung cancer. Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, reviews the press release from the FURVENT trial of firmonertinib, designed to be brain penetrant and holding Breakthrough Therapy designation, which missed its primary end point. By independent review, median PFS was 11 months at 240 mg, 8.4 months at 160 mg, and 9.5 months with chemotherapy, with response rates of 60%, 35%, and 33%. She notes the control arms lacked amivantamab because it was not yet standard, and wants safety, dose intensity, and demographic data. Dr Jänne calls the result surprising, wants central nervous system data, and sees a tough US first-line path.